Arcus Biosciences (RCUS) - Stock Price & Dividends

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company that focuses on developing and commercializing innovative cancer therapies in the United States.

The company's pipeline is filled with promising products, including Domvanalimab, an anti-TIGIT antibody that's currently in Phase 2 and Phase 3 clinical trials. This treatment has the potential to revolutionize cancer care by targeting a specific protein that helps cancer cells evade the immune system.

Another exciting product in the pipeline is AB308, an investigational anti-TIGIT monoclonal antibody that's in Phase 1b clinical trial. This treatment is being studied in people with advanced solid and hematologic malignancies, offering new hope for patients with limited treatment options.

Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, is another key product in the pipeline. This treatment is in Phase 2 clinical trial and has shown promising results in targeting cancer cells while sparing healthy cells.

Quemliclustat, a small-molecule CD73 inhibitor, is also making waves in the pipeline. This treatment is in Phase 1b and Phase 2 clinical trials, and its unique mechanism of action has the potential to overcome chemotherapy resistance in cancer cells.

Zimberelimab, an anti-PD-1 antibody, is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy. This treatment has shown impressive results in targeting a specific protein that helps cancer cells evade the immune system.

AB521, an oral and small-molecule inhibitor of HIF-2a, is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. This rare genetic disorder affects thousands of people worldwide, and Arcus Biosciences' treatment offers new hope for a cure.

In addition to its robust pipeline, Arcus Biosciences has formed strategic partnerships to accelerate its research and development. The company has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC. It has also partnered with BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases.

Arcus Biosciences, Inc. was founded in 2015 and is headquartered in Hayward, California. With its cutting-edge research and development, the company is poised to make a significant impact in the fight against cancer and other diseases.